RPL31P13: A Promising Drug Target / Biomarker (G100270983)

Target Name: RPL31P13

NCBI ID: G100270983

RPL31P13

Other Name(s): Ribosomal protein L31 pseudogene 13 | ribosomal protein L31 pseudogene 13 | RPL31_2_164

RPL31P13: A Promising Drug Target / Biomarker

RPL31P13 is a gene that encodes for a protein known as protamine alpha-glutamyltransferase 31 (P-GluT31). This gene is located on chromosome 17 at position 13 and is responsible for the production of a protein that plays a critical role in the metabolism of glutamyl amino acids, which are building blocks of proteins. Mutations in the RPL31P13 gene have been linked to a variety of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia.

The Importance of P-GluT31 in Cellular Signaling

P-GluT31 is a key enzyme in the transfer of glutamyl amino acids from the cell surface to the intracellular matrix. This process is involved in the regulation of cellular signaling and is a crucial step in the production of many proteins. The activity of P-GluT31 is regulated by a variety of factors, including pH, temperature, and substrate concentration.

In addition to its role in cellular signaling, P-GluT31 is also involved in the regulation of inflammation and stress responses. Studies have shown that P-GluT31 is involved in the production of reactive oxygen species (ROS), which can damage cellular components and contribute to the development of oxidative stress-induced diseases.

Drug Targeting and Biomarker

Due to its involvement in cellular signaling and its role in the regulation of inflammation and stress responses, P-GluT31 has been identified as a potential drug target for a variety of psychiatric and neurological disorders. Studies have shown that inhibition of P-GluT31 has been shown to reduce the production of ROS and improve the expression of genes involved in stress and inflammation.

In addition, research has also shown that individuals with certain genetic mutations, such as those found in the RPL31P13 gene, are at increased risk for developing certain psychiatric and neurological disorders. Therefore, the development of biomarkers for the RPL31P13 gene, such as P-GluT31, may be useful for the diagnosis and treatment of these disorders.

Conclusion

In conclusion, RPL31P13 is a gene that encodes for a protein that plays a critical role in the metabolism of glutamyl amino acids and the regulation of cellular signaling, stress, and inflammation. The development of P-GluT31 as a potential drug target and biomarker for a variety of psychiatric and neurological disorders is an promising area of research. Further studies are needed to fully understand the role of P-GluT31 in cellular signaling and its potential as a drug target.

Protein Name: Ribosomal Protein L31 Pseudogene 13

The "RPL31P13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL31P13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets